UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-42004
NEWGENIVF GROUP LIMITED
(Exact name of registrant as specified in its
charter)
36/39-36/40, 13th Floor, PS Tower
Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district
Watthana District, Bangkok 10110
Thailand
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
EXPLANATORY NOTE
Underwritten Offering
Underwriting Agreement
On November 19, 2026, NewGenIvf Group Limited
(the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp.
(“Aegis”), pursuant to which Aegis acted as the sole book-running manager and underwriter for an underwritten offering made on a
firm commitment basis (the “Offering”). The Company agreed to pay Aegis an underwriting discount equal to 9.0% of the gross proceeds of
the Offering and to reimburse Aegis for certain expenses, including the fees and disbursements of its counsel of up to $80,000. The Underwriting Agreement contains customary representations, warranties, and
indemnification provisions.
On November 20, 2026, the Company closed the Offering and issued (i) 9,501,148 Class A ordinary shares with no par value (the “Class
A Ordinary Shares”) (including 8,350,578 Class A Ordinary Shares issued upon the pre-closing exercise of pre-funded warrants) and
(ii) pre-funded warrants to purchase up to 61,927,422 Class A Ordinary Shares (the “Pre-Funded Warrants”), representing an
aggregate of 71,428,570 Class A Ordinary Shares issued or underlying the Pre-Funded Warrants. The offering price was $0.035 per Class
A Ordinary Share and $0.03499 per Pre-Funded Warrant, and the exercise price of each Pre-Funded Warrant is $0.00001 per Class A Ordinary
Share. The aggregate gross proceeds to the Company were approximately $2.5 million, before deducting underwriting discounts and commissions
and offering expenses. The Company expects to use the net proceeds from the Offering, together with its existing cash, for commercialization
and expansion of the Nodexus advanced cytometry technology and its assisted reproductive services platform, further strategic investments
in prediction-market and digital-asset/AI initiatives, its real estate interests in the UAE, and other general corporate purposes. The
Company’s management will retain broad discretion to apply these net proceeds. The Company will also apply approximately $625,000
of the gross proceeds of this Offering to repurchase $584,112 in principal amount of the Exchange Note as described below.
The Class A Ordinary Shares and Pre-Funded Warrants
were issued pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities
and Exchange Commission (the “SEC”) and declared effective by the SEC on November 12, 2026. A final prospectus supplement
and accompanying prospectus describing the terms of the Offering were filed with the SEC on November 20, 2026.
Lock-Up Agreements
Concurrently with the execution of the Underwriting
Agreement, the Company’s officers and directors holding the Company’s ordinary shares entered into lock-up agreements (the
“Lock-Up Agreements”) pursuant to which they agreed, subject to customary exceptions, not to offer, sell, or otherwise dispose
of any ordinary shares beneficially owned by them for sixty (60) days following the closing of the Offering.
Press Release
The Company announced the pricing of the Offering
in a press release issued on November 19, 2026, which is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein
by reference.
The Company announced the closing of the Offering
in a press release issued on November 20, 2026, which is furnished as Exhibit 99.2 to this Report on Form 6-K and incorporated herein
by reference.
Limited Waiver and Repurchase Agreement
On November 19, 2026, the Company entered into a Limited Waiver and
Repurchase Agreement (the “Waiver Agreement”) with the holder (the “Holder”) of the Company's outstanding senior
convertible note issued pursuant to an Amendment and Exchange Agreement dated August 11, 2026 (the “Exchange Note”). The Waiver
Agreement relates to the Offering.
Limited Waiver
Under the Waiver Agreement, the Holder agreed to a one-time, limited
waiver of a portion of the definition of “Alternate Conversion Price” in Section 32(g) of the Exchange Note. During the period
beginning on the tenth Trading Day (as defined in the Exchange Note) after the public announcement of the Offering and ending on and including
the seventieth Trading Day after that announcement (the “Waiver Period”), clause (y) of Section 32(g) of the Exchange Note
will be deemed to equal 76% of the lowest daily volume-weighted average price (“VWAP”) during the seven consecutive Trading
Days ending on and including the Trading Day immediately preceding delivery or deemed delivery of the applicable Conversion Notice. “Trading
Day” and “Conversion Notice” have the meanings assigned in the Exchange Note. The limited waiver modifies only the specified
clause during the Waiver Period and does not replace the entire definition of Alternate Conversion Price. Except as expressly provided
in the Waiver Agreement, the existing transaction and exchange documents remain in full force and effect. The limited waiver does not
constitute a waiver of other matters or a commitment to grant future waivers.
The Waiver Agreement provides that it becomes effective upon the later
of execution and delivery by both parties and the Company's payment in full of the agreed Waiver Legal Fee Reimbursement (as defined below).
Mandatory Repurchase
Under the Waiver Agreement, simultaneously with the initial closing
of the Offering, the Company is required to repurchase $584,112 of the outstanding principal of the Exchange Note for a repurchase price
of $625,000. Rather than paying that amount directly to the Holder, the Company has directed the Holder to reduce by $625,000 the cash
purchase price otherwise payable by the Holder for securities it acquires at the initial closing of the Offering. The repurchased portion
of the Exchange Note is automatically cancelled upon completion of the repurchase.
The Waiver Agreement states that the outstanding principal balance of the Exchange Note immediately before the Offering is $5,769,469
and that, after giving effect to the repurchase described above, the outstanding principal balance will be $5,185,357.
The Company also agreed to reimburse the Holder's
counsel a non-accountable amount of $15,000 for costs and expenses incurred in drafting and negotiating the Waiver Agreement (the “Waiver
Legal Fee Reimbursement”).
The foregoing descriptions of the Underwriting
Agreement, the Pre-Funded Warrants, the Lock-Up Agreements and the Waiver Agreement are qualified in their entirety by reference to the
full text of the form of each of the Underwriting Agreement, the Pre-Funded Warrant, the Lock-Up Agreement and the Waiver Agreement, attached
to this report as Exhibits 1.1, 4.1, 10.1 and 10.2, respectively, and incorporated herein by reference.
This Report on Form 6-K shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities described herein in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
Forward-Looking Statements
This Report on Form 6-K contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. securities laws. Forward-looking
statements are based on the Company’s current expectations, beliefs and assumptions regarding future events and performance. In
some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “expect,”
“plan,” “intend,” “estimate,” or “continue,” or the negatives of these terms or other
comparable terminology.
Forward-looking statements in this Report on Form
6-K include, among other things, statements about the intended use of the net proceeds of the Offering. These forward-looking statements
are subject to risks, uncertainties, and assumptions that are difficult to predict. Actual results may differ materially from those expressed
or implied in the forward-looking statements. Factors that could cause such differences include, but are not limited to, market conditions,
the Company’s ability to deploy the net proceeds as currently contemplated, and other risks described in the Company’s filings
with the SEC.
The Company undertakes no obligation to update
or revise any forward-looking statements contained herein, except as required by applicable law.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 1.1 |
|
Form of Underwriting Agreement |
| 4.1 |
|
Form of Pre-Funded Warrant |
| 10.1 |
|
Form of Lock-Up Agreement |
| 10.2 |
|
Form of Limited Waiver and Repurchase Agreement |
| 99.1 |
|
Press Release, dated November 19, 2026 |
| 99.2 |
|
Press Release, dated November 20, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: November 20, 2026
| |
NEWGENIVF GROUP LIMITED |
| |
|
|
| |
By: |
/s/ Wing Fung Alfred Siu |
| |
Name: |
Wing Fung Alfred Siu |
| |
Title: |
Chairman of the Board and Director |
Exhibit 99.1
NewGenIvf Group Limited Announces Pricing of
$2.5 Million Underwritten Offering
BANGKOK, November 19, 2026 (GLOBE NEWSWIRE)
-- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced
the pricing of a firm commitment underwritten offering with gross proceeds to the Company expected to be approximately $2.5 million, before
deducting underwriting fees and other offering expenses payable by the Company.
The offering consists of 71,428,570 Class A Ordinary
Shares (or Pre-Funded Warrants in lieu thereof). The offering price per Class A Ordinary Share is $0.035 (or $0.03499 for each Pre-Funded
Warrant, which is equal to the offering price per Class A Ordinary Share to be sold in the offering minus an exercise price of $0.00001
per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full.
For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one
basis.
Aggregate gross proceeds to the Company are expected
to be approximately $2.5 million. The transaction is expected to close on or about November 20, 2026, subject to the satisfaction of customary
closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate
purposes and working capital.
Aegis Capital Corp. is acting as the sole book-running
manager for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S.
counsel to Aegis Capital Corp.
The offering is being made pursuant to an effective
shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and
declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of
the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic
copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital
Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com,
or by telephone at +1 (212) 813-1010.
Interested parties should read in their entirety
the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated
by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such
offering.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
About NewGenIvf Group Limited
NewGenIvf Group Limited is a technology-forward,
diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions.
The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital,
focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s
legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information
contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
Forward-Looking Statements
The foregoing material may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including
without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use
of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,”
“plan,” “believe,” “potential,” “should,” “continue” or the negative versions
of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking
statements are based on information currently available to the Company and its current plans or expectations and are subject to a number
of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize,
or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected,
intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable,
the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities
laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to
actual results.
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
Exhibit 99.2
NewGenIvf Group Limited Announces Closing of
$2.5 Million Underwritten Offering
BANGKOK, November 20, 2026 (GLOBE NEWSWIRE)
-- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced
the closing of its previously announced firm commitment underwritten offering with gross proceeds to the Company of approximately $2.5
million, before deducting underwriting fees and other offering expenses payable by the Company.
The offering consisted of 71,428,570 Class A Ordinary
Shares (or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”)). At closing,
the offering comprised 9,501,148 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 61,927,422 Class A Ordinary Shares.
The offering price per Class A Ordinary Share was $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price
per Class A Ordinary Share sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are
immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the
number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.
Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on November 20, 2026. The Company expects
to use the net proceeds from the offering, together with its existing cash, for commercialization and expansion of the Nodexus advanced
cytometry technology and our assisted reproductive services platform, further strategic investments in prediction-market and digital-asset/AI
initiatives, our real estate interests in the UAE, and other general corporate purposes. Our management will retain broad discretion to
apply these net proceeds. We will also apply approximately $625,000 of the gross proceeds of this offering to repurchase $584,112 in principal
amount of the Exchange Note. The Company’s Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “NIVF”.
Aegis Capital Corp. acted as the sole book-running
manager for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel
to Aegis Capital Corp.
The offering was made pursuant to an effective
shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and
declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of
the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies
of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate
Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212)
813-1010.
Interested parties should read in their entirety
the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated
by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
About NewGenIvf Group Limited
NewGenIvf Group Limited
is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and
reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah,
United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and
longevity products and solutions. The Company’s legacy business includes IVF and assisted reproductive treatment services across
Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated
by reference into this press release.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including
without limitation statements regarding the anticipated use of proceeds from the offering, the Company’s product development and
business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees
of future actions or performance. These forward-looking statements are based on information currently available to the Company and its
current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should
one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected
in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. For a discussion
of the risks and uncertainties that could cause actual results to differ materially, see the section entitled “Risk Factors”
in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and in the final prospectus supplement relating
to the offering. Except as required by applicable law, including the securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these statements to actual results.
Investor Contact:
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com